

Dual Versus Mono Antiplatelet Therapy for Acute Non- Cardio Embolic Ischemic Stroke or Transient Ischemic Attack, an Efficacy and Safety Analysis - Updated Meta-Analysis

Christessa Emille Que Albay*, Frederick Gavril D. Leyson and Federick C. Cheng

Cardinal Santos Medical Center, Philippines



Abstract

New evidence on the efficacy and safety of dual antiplatelet therapy for secondary stroke prevention have been realized in the recent years. An updated meta-analysis was done to determine the effect of the various dual antiplatelets (including ticagrelor and cilostazol) vs aspirin alone on recurrence rate of ischemic stroke, cardiovascular morbidity and mortality, and its safety profile as reported through major bleeding. Methods includes PubMed, Cochrane and Science Direct data bases were utilized, RCTs evaluating dual antiplatelet vs. mono antiplatelet therapy for acute ischemic stroke or transient ischemic attack within < 72 hours from ictus were searched up to July 2019. Risk ratio at 95% confidence intervals were calculated to evaluate stroke recurrence, cardiac events and mortality, and major bleeding.



Biography:

Christessa Emille Que Albay is currently a 2nd year medical resident in Cardinal Santos Medical Center. She has earned her Doctor of Medicine Degree from the University of the Philippines, Manila and her Bachelor of Science in Chemistry from the University of the Philippines Diliman, graduating Magna Cum Laude. To date, researches conducted by Dr. Albay have been included in oral presentations in local symposiums such as the Philippine Chemistry Congress, Joint Conference of 2012 Asia Pacific Conference on Analytical science and 3rd Regional Electrochemistry Meeting of Southeast Asia last 2012.

Speaker Publications:

1. "Aoki J, Yasuyuki I, Takao U, et al. Acute aspirin plus Cilostazol dual therapy for Noncardioembolic stroke patients within 48 hours of symptom onset. J Am Heart Assoc. 2019;8:e012652
2. "Wang Y, Johnston SC, CHANCE Investigators. Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. Am Heart J. 2010;160:380–6
3. "Johnston SC, Easton JD, Farrant M, et al. Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. Int J Stroke. 2013;8:479–83
4. "Daniel H, Spence JD. Antiplatelet therapy in ischemic stroke and transient ischemic attack. An Overview of Major Trials and Meta-Analyses. J Am Heart Assoc. 2019;50:773–8.
5. "Tantry US, Bliden KP, Gurbel PA. AZD6140. Expert Opin Investig Drugs. 2007;16:225–9.

[9th International Conference on Brain Disorders & Therapeutics](#); August 21-22, 2020.

Abstract Citation:

Christessa Emille Que Albay, Dual versus mono antiplatelet therapy for acute non- cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis - updated meta-analysis, Brain Disorders 2020, 9th International Conference on Brain Disorders & Therapeutics; August 21-22, 2020.

<https://braindisorders.neuroconferences.com/abstract/2020/dual-versus-mono-antiplatelet-therapy-for-acute-non-cardio-embolic-ischemic-stroke-or-transient-ischemic-attack-an-efficacy-and-safety-analysis-updated-meta-analysis>